ReviewCancer journal (Sudbury, Mass.)
Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Histidine-improved cancer immunosurveillance.Oncoimmunology · 2026Article
- Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities.British journal of cancer · 2026Article
- Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis.Immunity, inflammation and disease · 2026Article
- Metabolic syndrome and immune-related adverse events.Cancer immunology, immunotherapy : CII · 2026Article
- Lung cancer in patients with scleroderma-associated interstitial lung disease: Case series and implications for screening.Respiratory medicine case reports · 2026Article
- Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.Future oncology (London, England) · 2025Article
- Genetic haplotypes inJournal for immunotherapy of cancer · 2025Article
- Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy.Future oncology (London, England) · 2025Article
- Inflammatory Pathways to Carcinogenesis: Deciphering the Rheumatoid Arthritis-Lung Cancer Connection.Cancers · 2025Review
- SITC strategic vision: prevention, premalignant immunity, host and environmental factors.Journal for immunotherapy of cancer · 2025Review
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.BMC cancer · 2024Article
- Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.Frontiers in immunology · 2024Article
- T-cell tolerant fraction as a predictor of immune-related adverse events.Journal for immunotherapy of cancer · 2023Article
- Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.Cancer medicine · 2023Article
- Article
- Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.Journal of medical case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitor (ICI) therapy is now in widespread clinical use for the treatment of lung cancer. Although patients with autoimmune disease and other comorbidities were excluded from initial clinical trials, emerging real-world experience suggests that these promising treatments may be administered safely to individuals with inactive low-risk autoimmune disease such as rheumatoid arthritis or psoriasis, mild to moderate renal and hepatic dysfunction, and certain chronic viral infections. Considerations for ICI in autoimmune disease populations include exacerbations of the underlying autoimmune disease, increased risk of ICI-induced immune-related adverse events, and potential for compromised efficacy if patients are receiving chronic immunosuppression. Immune checkpoint inhibitor use in higher-risk autoimmune conditions, such as myasthenia gravis or multiple sclerosis, requires careful evaluation on a case-by-case basis. Immune checkpoint inhibitor use in individuals with solid organ transplant carries a substantial risk of organ rejection. Ongoing research into the prediction of ICI efficacy and toxicity may help in patient selection, treatment, and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.